Workflow
伯乐生命医学(BIO)
icon
搜索文档
Bio-Rad(BIO) - 2019 Q2 - Earnings Call Transcript
2019-08-02 18:47
Bio Rad Laboratories (NYSE:BIO) Q2 2019 Earnings Conference Call August 1, 2019 5:00 PM ET Company Participants Ronald Hutton - VP & Treasurer Ilan Daskal - EVP & CFO Norman Schwartz - Chairman, CEO & President Andrew Last - EVP & COO Annette Tumolo - EVP & President of Life Science Group John Hertia - EVP & President, Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Goldman Sachs Group Mitchell Petersen - Barclays Bank Daniel Leonard - Deutsche Bank Brandon Couillard - Jefferies O ...
Bio-Rad(BIO) - 2019 Q1 - Quarterly Report
2019-05-11 04:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...
Bio-Rad(BIO) - 2019 Q1 - Earnings Call Transcript
2019-05-09 12:09
Bio-Rad Laboratories. Inc. (NYSE:BIO) Q1 2019 Earnings Conference Call May 8, 2019 5:00 PM ET Company Participants Ron Hutton - Vice President and Treasurer Ilan Daskal - EVP and CFO Norman Schwartz - CEO Andy Last - COO Annette Tumolo - President, Life Science Group John Hertia - President, Clinical Diagnostics Group Conference Call Participants Mike Sarcone - Deutsche Bank Brandon Couillard - Jefferies Patrick Donnelly - Goldman Sachs Jack Meehan - Barclays Operator Good day, ladies and gentlemen, and wel ...
Bio-Rad(BIO) - 2018 Q4 - Annual Report
2019-03-30 09:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its ch ...
Bio-Rad(BIO) - 2018 Q4 - Earnings Call Transcript
2019-03-02 00:20
Bio-Rad Laboratories, Inc (NYSE:BIO) Q4 2018, Earnings Conference Call February 28, 2019 5:00 PM ET Company Participants Ron Hutton – Vice President and Treasurer Christine Tsingos – Executive Vice President and Chief Financial Officer Norman Schwartz – Chief Executive Officer John Hertia – President of our Clinical Diagnostics Group Annette Tumolo – President of our Life Science Group Conference Call Participants Brandon Couillard – Jefferies LLC Patrick Donnelly – Goldman Sachs Dan Leonard – Deutsche Bank ...
Bio-Rad Laboratories (BIO) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
2019-01-10 04:57
Bio-Rad Laboratories, Inc. J.P. Morgan Healthcare Conference 2019 BIO RAD Forward-Looking Statements Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our investment in high growth emerging markets and new products and technologies, our new focus on lab to clinic solutions, improvements to our operational efficiency and our future financial performance. Forward ...